TR
Insider
Timothy Rolph
Chief Scientific OfficerTimothy Rolph (Chief Scientific Officer) filed 13 Form 4 reports in the past 24 months (0 purchases, 13 sales, 1 filed past the two-business-day deadline), most often in AKRO. The largest single filing was $2.0M of AKRO (37,500 sh across 3 lots, as filed), executed Jun 5 2025. Data as of Nov 9 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
13
0 buys · 13 sells · 1 late
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.8M
shares × price, as filed
Last traded
Oct 7 2025
Filed Oct 9 2025
Volume by month
Buys $0
Sells $8.8M
Shares × price, as filed · by filing month · past 24 months
Most traded names
AKRO
AKRO
0 buys · 13 sells
13 filings
Recent filings
AKROSALE
Akero Therapeutics, Inc.
View filing →
$135K3,750 sh × $36.05
Exec Apr 7 2025
Filed Apr 10 2025 · 5:30 PM ET † AKROSALE Akero Therapeutics, Inc. View filing → $557K
12,500 sh across 2 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.1M
18,750 sh across 2 lots
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.7M
31,250 sh across 3 lots
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $118K
3,800 sh × $31.10
Exec Dec 17 2024
Filed Dec 18 2024 · 5:30 PM ET